Together With
Today is Monday, June 22, 2026.
The Early Bird Index today is 92.04.
New to this newsletter? Sign up here
PRESENTED BY STRATIFIND
Can Precision Oncology Become More Precise? Stratifind Thinks So.
Cancer remains one of the largest and most important healthcare markets in the world, yet selecting the right treatment for the right patient remains one of oncology’s greatest challenges. Physicians routinely choose among chemotherapy, immunotherapy, targeted therapies, radiation, and combination approaches, often with limited information about which treatment is most likely to benefit a particular patient.
Stratifind is developing RainDanceEQ™, a precision oncology platform designed to help physicians make more informed treatment decisions through a more comprehensive understanding of each patient’s cancer. By integrating multiple layers of tumor information and advanced analytics into a single actionable report, the company aims to provide insights that go beyond traditional testing approaches.
Founded by healthcare investment banker Igor Sokolovsky and physician-scientist Dr. Partha Ray, Stratifind is pursuing an opportunity at the intersection of molecular diagnostics, precision medicine, and oncology decision support. Successful oncology diagnostics companies have created substantial value for patients, providers, and investors alike, and Stratifind seeks to establish a differentiated position within this growing sector.
The company is currently conducting a financing round through Netcapital and welcomes conversations with investors, family offices, healthcare professionals, and strategic partners interested in the future of cancer diagnostics and precision oncology.
Disney's Nostalgia Cash Cow 🎬
Amid a lackluster year, investors of Walt Disney $DIS ( ▲ 3.0% ) may finally have something to celebrate following the strong debut of ‘Toy Story 5’ at the box office this past weekend.
Details: Disney's ‘Toy Story 5’ just debuted with $160 million domestically and $312 million globally. It was the top box office opening weekend of 2026. It is also the largest start for any film in the ‘Toy Story’ franchise.
Background: The success of ‘Toy Story 5’ follows the typical Disney playbook of releasing sequels and remakes that evoke nostalgic memories of past hit movies.
Early Bird’s Nest Egg Gains: For Disney investors, this is a clear positive: The box office success signals strong demand for one of Disney’s most valuable franchises and supports the company’s studio, licensing, and brand momentum.
The box office result is not just about ticket sales; it is evidence that Disney can still monetize premium franchises at scale. A strong opening also reduces the risk that the film becomes a drag on earnings expectations, which can matter for sentiment around Disney stock in the short term.
This does not mean Disney’s stock will automatically re-rate higher on one weekend alone, because the market also cares about parks, streaming, ad trends, margins, and management execution.
Final Thoughts: Disney’s stock is down 7.12% this year, although the price has stabilized over the past month.
Notables
Notable Earnings Today: Fervo Energy (Nasdaq: FRVO), Outdoor Holding Company (Nasdaq: POWW).
Notable IPOs Today: CH4 Natural Solutions Corporation (NYSE: MTNE), Quantum Leap Acquisition Corp (NYSE: QLEP), Forefront Tech Holdings Acquisition Corp Class A Ordinary Shares (Nasdaq: FTHA), General Catalyst Global Resilience Merger Corp. Class A Ordinary Shares (Nasdaq: GCGR), Happen, Inc. Common Stock (Nasdaq: HAPN), Collective Acquisition Corp. II Class A Ordinary Shares (Nasdaq: CAII), Keystone Acquisition Corp. Class A Ordinary Shares (Nasdaq: KEYY), Mountain Crest Acquisition 6 Corp. Ordinary Shares (Nasdaq: MCAH).
Notable Equity Crowdfunding Campaigns Ending Today: Collider (Crowdcube), Exogene (Crowdcube), QPlay (Crowdcube).
Notable Economic Events Today: N/A.
MoonLake's FDA Submission
Clinical-stage biotechnology company MoonLake Immunotherapeutics $MLTX ( ▲ 0.1% ) said on Sunday that it will submit a filing to the FDA at the end of September for a new drug.
Details: The drug, Sonelokimab, is meant to fight skin disease and showed consistent improvement in its latest clinical trial. MoonLake will discuss the results during an Investor Day today.
Final Thoughts: MoonLake’s stock is up 60.75% in 2026. However, in the past 12 months, the stock has been down over 57% after a collapse in September 2025.
Solana’s Slight Sunday Jump
It was a slow day for cryptocurrency prices on Sunday, yet Solana $SOL ( ▼ 0.14% ) managed to rise by about 1%.
Final Thoughts: Solana’s price is up nearly 4% in the past week.
Trends to Watch
More Volatility: Kevin Warsh’s push to axe Fed guidance may lift US borrowing costs, investors warn (Financial Times)
Is It Time To Panic: America’s savings rate has plunged (The Economist)
Pain at the Pump: Oil rises after Trump threatens fresh strikes on Iran, overshadowing peace talks (CNBC)
Crypto Attack: Ethereum's biggest 'sandwich' bot drained of $7.5 million in ironic exploit (CoinDesk)
Deception: They Looked Like They Were Getting Rich on Polymarket—but None of It Was Real (Wall Street Journal)
Thank you for reading!
Forward to a friend and tell them to sign up here.
Pick winning stocks: Upgrade to Early Bird Prime.
Become a smarter investor: Get Early Bird Exclusives
Want more investing tips? Listen to the podcast.
Show Your Support: Buy Me a Coffee.
Questions or comments? Hit reply to reach out.
The contents of Early Bird are intended for informational and entertainment purposes only. They do not constitute trade or investment recommendations, and they are not financial or legal advice. Readers are encouraged to consult licensed professionals for personalized guidance regarding their financial or legal situations.
